Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 2/20 | 0.32 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.32 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14850463 | 1.00 | MME (0.32) | MMEROCK2ROCK1ACACBITGA4 | |
| SCHEMBL8911903 | 0.86 | ACACB (0.33) | MMEACACBITGA4ITGB7ALDH1A1 | |
| SCHEMBL888696 | 0.86 | ACACB (0.33) | MMEACACBITGA4ITGB7ALDH1A1 | |
| SCHEMBL10122822 | 0.86 | ACACB (0.33) | MMEACACBITGA4ITGB7ALDH1A1 | |
| SCHEMBL14886286 | 0.86 | MME (0.31) | MMEACACBITGA4ITGB7 | |
| SCHEMBL10120407 | 0.85 | MME (0.31) | MMEACACBITGA4ITGB7 | |
| SCHEMBL17641845 | 0.82 | — | — | |
| SCHEMBL19487728 | 0.78 | — | — | |
| SCHEMBL13187470 | 0.77 | ITGB2 (0.49) | ALDH1A1 | |
| SCHEMBL12824382 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9676802-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-9156818-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9127021-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-9000020-B2 | Linked dibenzimidazole antivirals | ENANTA PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8933110-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8927709-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20140341851-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8822700-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8673954-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8653070-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8637561-B2 | Linked diimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8623814-B2 | Antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130295049-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC (US) | 2013-11-07 | — | — | US | disclosed |
| US-8507522-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8426458-B2 | Hepatitis C Virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8420686-B2 | Linked diimidazole antivirals | ENANTA PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110300104-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
| US-20110206637-A1 | ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | MME 2377/4885ROCK2 3696/4885ROCK1 3333/4885 |
| US-20110300104-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | MME 596/4885ROCK2 3028/4885ROCK1 2263/4885 |
| US-20110206637-A1 | ANTIVIRAL AGENTS | EIF2AK2, ZC3HAV1, MAVS | MME 644/4885ROCK2 3668/4885ROCK1 2404/4885 |
| US-20130295049-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | EIF2AK2, ZC3HAV1, NSUN2 | MME 1757/4885ROCK2 4343/4885ROCK1 3998/4885 |
| US-20140341851-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | MME 2377/4885ROCK2 3696/4885ROCK1 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.